Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose

Radiotherapy and Oncology

Volumn 93, Issue 2, 2009, Pages 180-184

  van Vulpen, Marco ^a   van den Berg, Cornelis A T ^a   Moman, Maaike R ^a   van der Heide, Uulke A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Dose response relationship; Local recurrence; Prostate; Radiotherapy; Tumor control probability

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RADIATION RESPONSE; RECURRENT CANCER; TREATMENT PLANNING;

AGED; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 70350504890     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.06.033     Document Type: Article

References (28)

1. Lu-Yao G.L., and Yao S.L. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349 (1997) 906-910
2. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
3. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
4. Cellini N., Morganti A.G., Mattiucci G.C., Valentini V., Leone M., Luzi S., et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53 (2002) 595-599
5. Rouvière O., Valette O., Grivolat S., Colin-Pangaud C., Bouvier R., Chapelon J.Y., et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings. Urology 63 (2004) 922-927
6. Pucar D., Hricak H., Shukla-Dave A., Kuroiwa K., Drobnjak M., Eastham J., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69 (2007) 62-69
7. Haider M.A., Chung P., Sweet J., Toi A., Jhaveri K., Ménard C., et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 425-430
8. Westphalen A.C., McKenna D.A., Kurhanewicz J., and Coakley F.V. Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J Endourol 22 (2008) 789-794
9. Menard C., Smith I.C., Somorjai R.L., Leboldus L., Patel R., Littman C., et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 50 (2001) 317-323
10. Nederveen A.J., van der Heide U.A., Hofman P., Welleweerd H., and Lagendijk J.J. Partial boosting of prostate tumours. Radiother Oncol 61 (2001) 117-126
11. Dehnad H., Nederveen A.J., van der Heide U.A., van Moorselaar R.J., Hofman P., and Lagendijk J.J. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol 67 (2003) 295-302
12. Van der Heide U.A., Kotte A.N., Dehnad H., et al. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol 82 (2007) 38-45
13. Kotte A.N., Hofman P., Lagendijk J.J., et al. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 69 (2007) 419-425
14. Battermann J.J., Boon T.A., and Moerland M.A. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 71 (2004) 23-28
15. Tofts P.S., Brix G., Buckley D.L., Evelhoch J.L., Henderson E., Knopp M.V., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 10 (1999) 223-332
16. Heidenreich A., Aus G., Bolla M., Joniau S., Matveev V.B., Schmid H.P., et al., European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
17. Van der Poel H.G., Beetsma D.B., van Boven H., and Horenblas S. Perineal salvage prostatectomy for radiation resistant prostate cancer. Eur Urol 51 (2007) 1565-1571
18. Padhani A.R., MacVicar A.D., Gapinski C.J., Dearnaley D.P., Parker G.J., Suckling J., et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology 218 (2001) 365-374
19. Van Gellekom M.P., Moerland M.A., Kal H.B., and Battermann J.J. Biologically effective dose for permanent prostate brachytherapy taking into account postimplant edema. Int J Radiat Oncol Biol Phys 53 (2002) 422-433
20. Pieters B.R., Van der Grient J.N., Blank L.E., Koedooder K., Hulshof M.C., and De Reijke T.M. Minimal displacement of novel self-anchoring catheters suitable for temporary prostate implants. Radiother Oncol 80 (2006) 69-72
21. Nahum A.E., Movsas B., Horwitz E.M., Stobbe C.C., and Chapman J.D. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 57 (2003) 391-401
22. Roach III M., Hanks G., Thames Jr. H., Schellhammer P., Shipley W.U., Sokol G.H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
23. Nguyen P.L., D'Amico A.V., Lee A.K., and Suh W.W. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110 (2007) 1417-1428
24. Parker G.J., Roberts C., Macdonald A., Buonaccorsi G.A., Cheung S., Buckley D.L., et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 56 (2006) 993-1000
25. Cheikh A.B., Girouin N., Colombel M., Maréchal J.M., Gelet A., Bissery A., et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 19 (2009) 770-778
26. Pound C.R., Brawer M.K., and Partin A.W. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 3 (2001) 72-84
27. van Haaren P.M., Bel A., Hofman P., van Vulpen M., Kotte A.N., and van der Heide U.A. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiother Oncol 90 (2009) 291-298
28. Nederveen A.J., Dehnad H., van der Heide U.A., van Moorselaar R.J., Hofman P., and Lagendijk J.J. Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiother Oncol 68 (2003) 81-88